CDK4 and cancer: One explanation for varying perceptions could be different frames of reference; while providers may compare CDK4/6 inhibitor symptom burden to that of more toxic cancer treatments (e.g., cytotoxic chemotherapy), patients may not have the same experiences for comparison.